FIGO GRADE 2 ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Clinical trials for FIGO GRADE 2 ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new FIGO GRADE 2 ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for FIGO GRADE 2 ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy shows promise for Tough-to-Treat endometrial cancer
Disease control OngoingThis study tests whether adding the drug ipatasertib to standard hormone therapy (megestrol acetate) works better than hormone therapy alone for people with recurrent or metastatic endometrioid endometrial cancer. About 96 participants with grade 1 or 2 cancer will receive either…
Matched conditions: FIGO GRADE 2 ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo aims to outsmart Chemo-Resistant ovarian cancer
Disease control OngoingThis early-phase trial tests a new drug called peposertib combined with a standard chemotherapy (PLD) in people with ovarian or related cancers that have stopped responding to platinum-based treatment. The main goal is to find the safest dose and understand side effects. About 54…
Matched conditions: FIGO GRADE 2 ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Could a hormonal IUD replace surgery for some uterine cancers?
Disease control OngoingThis study looks at whether a hormonal intrauterine device (IUD) alone or combined with the drug everolimus can treat precancerous changes or very early-stage endometrial cancer. About 100 women with these conditions will receive the IUD, and some will also take everolimus if the…
Matched conditions: FIGO GRADE 2 ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New study aims to predict cancer return in Low-Risk patients
Knowledge-focused OngoingThis study looks at whether molecular testing and lymph node mapping can help predict if low-risk endometrial cancer will return after surgery. About 518 patients with early-stage, low-grade cancer will be followed for two years. The goal is to improve follow-up care by identifyi…
Matched conditions: FIGO GRADE 2 ENDOMETRIAL ENDOMETRIOID ADENOCARCINOMA
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC